The Maverick line of qPCR instruments from Anitoa Systems—a Silicon Valley-based biotechnology company specializing in portable molecular testing hardware—has received U.S. Food and Drug Administration registration and device listing as class II 510(k) exempt medical devices.
The Maverick line of qPCR devices offers rapid, on-site testing of infectious pathogens in humans, food, and the environment. Since the outbreak of COVID-19 last year, Maverick qPCR devices have been used around the world to test for COVID-19, providing sample-to-results in less than 45 minutes with standard RT-PCR chemistry.
Available in 4, 8, and 16 well formats, Maverick qPCR instruments include a low-light-sensitive complementary metal-oxide-semiconductor (CMOS) 4-channel fluorescence optics system that allows highly multiplexed DNA detection without the need for field calibration. In addition, Maverick’s cloud-based software enables data storage and retrieval.
“We are excited to offer laboratories throughout North America and other international markets a portable solution for rapid and on-site nucleic acid tests to help combat diseases such as COVID-19,” says Zhimin Ding, PhD, CEO of Anitoa Systems. “We believe our portable qPCR instruments and software solutions offer features that meet the needs of customers seeking highly sensitive detection of key life-threatening pathogens while being extremely cost effective.”
For more information, visit Anitoa Systems.
Featured Image: Anitoa received FDA registration and class II exempt device listing for its Maverick line of portable qPCR instruments, including the Maverick Compact Real Time PCR Instrument Model MQ16 (shown here). Photo: Anitoa Systems
